Picard Medical, Inc. (PMI)

Picard Medical, Inc. (PMI) Healthcare & Pipeline Overview

Picard Medical, Inc. (PMI) is a healthcare company focused on the development and commercialization of innovative medical devices, including the SynCardia TAH, which addresses critical cardiac conditions, positioning itself in a competitive landscape with significant growth potential.

What Is the Investment Thesis for PMI?

Picard Medical, Inc. presents a unique investment thesis driven by its innovative product offerings, particularly the SynCardia TAH, which addresses a critical gap in cardiac care. With a market cap of $266.45M, PMI operates in a sector projected to grow significantly due to increasing incidences of heart disease and advancements in medical technology. The company’s gross margin stands at 15.2%, indicating potential for improvement as production scales. However, PMI faces challenges, including a negative profit margin of -545.0%, necessitating close monitoring of operational efficiencies and cost management strategies. The company's ability to capture market share in the evolving medical device landscape will be a key driver of its long-term growth, particularly as it navigates competition from larger entities and adapts to emerging technologies.

Based on FMP financials and quantitative analysis

PMI Key Highlights

• Market cap of $266.45M reflects a growing presence in the medical device sector.
• Gross margin of 15.2% indicates potential for operational improvement as the company scales.
• Negative profit margin of -545.0% highlights the need for strategic cost management.
• Employs approximately 75 individuals, fostering innovation in medical device commercialization.
• Established in 2021, showcasing rapid growth and development in a competitive industry.

Who Are PMI's Competitors?

PMI is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are PMI's Key Strengths?

• Innovative product offerings, particularly the SynCardia TAH.
• Strong focus on the entire commercialization process of medical devices.
• Established presence in multiple international markets.
• Dedicated workforce of approximately 75 employees fostering innovation.

What Are PMI's Weaknesses?

• Negative profit margin indicating potential financial instability.
• Limited brand recognition compared to larger competitors.
• Dependence on a single product line, the SynCardia TAH.
• Relatively new company with limited operational history.

What Are the Key Risks for PMI?

• Financial-distress signal — its Altman Z-Score of -5.00 sits in the distress zone (elevated bankruptcy risk).

What Are the Growth Opportunities for PMI?

• Expansion of SynCardia TAH: The total artificial heart market is projected to grow significantly, with an estimated market size of $2 billion by 2030. PMI's innovative SynCardia TAH addresses a critical need for patients with advanced heart disease, positioning the company to capture a substantial share of this growing market.
• International Market Penetration: PMI has the potential to expand its market presence in Europe and other international regions. With increasing healthcare investments and a rising prevalence of cardiac diseases globally, the company can leverage its innovative products to tap into new markets, enhancing revenue streams over the next five years.
• Technological Advancements: The medical device sector is rapidly evolving, with advancements in materials and technology enhancing product efficacy. PMI can invest in research and development to innovate and improve existing products, ensuring competitiveness and meeting the changing needs of healthcare providers and patients.
• Strategic Partnerships: Forming strategic alliances with healthcare providers and research institutions can enhance PMI's product development and distribution capabilities. Collaborations can lead to increased market access and shared resources, driving growth and innovation over the next few years.
• Regulatory Approvals: Gaining regulatory approvals for new products can significantly impact PMI's growth trajectory. The company is positioned to expedite its product offerings in the market, particularly in regions with favorable regulatory environments, potentially increasing its market share and revenue.

What Opportunities Does PMI Have?

• Growth in the total artificial heart market projected to reach $2 billion by 2030.
• Potential for expanding international market presence.
• Advancements in technology can enhance product offerings.
• Strategic partnerships may lead to increased market access.

What Threats Does PMI Face?

• Intense competition from established players in the medical device sector.
• Potential disruptions from emerging technologies in cardiac care.
• Regulatory challenges that may delay product approvals.
• Economic fluctuations impacting healthcare spending.

What Are PMI's Competitive Advantages?

• Specialization in total artificial heart technology provides a competitive edge.
• Established distribution network enhances market access and customer reach.
• Innovative product offerings address critical gaps in cardiac care.
• Strong focus on research and development fosters continuous innovation.
• Partnerships with healthcare providers bolster credibility and market presence.

What Does PMI Do?

Founded in 2021, Picard Medical, Inc. is a healthcare company that specializes in the entire process of medical device commercialization, including design, manufacturing, production, distribution, marketing, and sales. The company is headquartered in Tucson, Arizona, and operates as a direct subsidiary of Hunniwell Picard I, LLC. A standout product in its portfolio is the SynCardia TAH, a sophisticated total artificial heart designed to replace a failing human heart in patients suffering from advanced cardiac disease. This innovative device is crucial for individuals who are not candidates for traditional heart transplants, providing a life-saving solution to a significant medical need. PMI's market presence extends beyond the United States to Europe and other international regions, showcasing its ambition to address global healthcare challenges. The company employs approximately 75 individuals, fostering a culture of innovation and dedication to improving patient outcomes. As PMI continues to expand its product offerings and market reach, it aims to solidify its position in the medical devices sector, competing against established players while leveraging its specialized expertise in cardiac solutions.

What Products and Services Does PMI Offer?

• Develop and commercialize innovative medical devices.
• Specialize in total artificial heart solutions for advanced cardiac disease.
• Manage the entire lifecycle of medical device commercialization.
• Operate a distribution network across the United States and internationally.
• Focus on improving patient outcomes through advanced technology.
• Collaborate with healthcare providers for product integration.

How Does PMI Make Money?

• Generate revenue through the sale of medical devices, primarily the SynCardia TAH.
• Leverage partnerships with healthcare institutions for distribution and marketing.
• Engage in research and development to innovate and enhance product offerings.
• Focus on expanding market presence in both domestic and international markets.
• Utilize a comprehensive approach to medical device commercialization, from design to sales.

What Industry Does PMI Operate In?

The medical device industry is experiencing robust growth, driven by increasing healthcare expenditures and advancements in technology. The global market is projected to expand significantly, with a focus on innovative solutions for chronic diseases, particularly cardiovascular conditions. Picard Medical, Inc. operates within this dynamic landscape, competing against established players while addressing critical needs in cardiac care. The demand for advanced medical devices, such as artificial hearts, is expected to rise, positioning PMI favorably for future growth as it capitalizes on emerging trends and technological advancements.

Who Are PMI's Key Customers?

• Hospitals and healthcare facilities requiring advanced cardiac solutions.
• Patients suffering from advanced heart disease needing life-saving interventions.
• Healthcare providers seeking innovative medical devices for treatment.
• International markets with increasing demand for cardiac care solutions.
• Research institutions collaborating on medical device advancements.

PMI Valuation & Market Position

With a $266.45M market cap, Picard Medical, Inc. sits in the micro-cap segment of the market. Relative to its peer group, PMI's quantitative score of 13/100 is below the peer average of 76/100.

FY2026 estForward Outlook

Wall Street analysts project Picard Medical, Inc. revenue of about $5.5M for fiscal 2026, with EPS near $-0.17.

F-Score 4/9Financial Health

Picard Medical, Inc.'s Piotroski F-Score is 4/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of -5.00 places it in the distress zone, a signal of elevated financial risk.

ROE 499%Key Financial Metrics

Return on equity for Picard Medical, Inc. stands at 499.2%, a gauge of how efficiently it converts shareholder capital into profit. Its free cash flow yield is -6.5%, a gauge of the cash the business throws off relative to its market value. A current ratio of 0.75 means current liabilities exceed short-term assets, a liquidity point worth watching.

PMI Financials

PMI Latest News

PMI Analyst Consensus

PMI MoonshotScore

Latest Picard Medical, Inc. Analysis

PMI Healthcare Stock FAQ

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources